Original news and analysis on international IP policy
A high-level meeting convened by the World Health Organization yesterday on the issue of access to and financing of Ebola vaccines resulted in a set of commitments, though not with sufficient urgency for those working on the ground. The pharmaceutical industry committed to scale up production, while donors pledged funds without disclosing how deep their pockets might be.
PARIS –Life sciences stakeholders at a recent conference explored matters associated with market access in the BRICS (Brazil, Russia, India, China, South Africa) and in the Middle East and North Africa regions.
World Trade Organization Director General Roberto Azevêdo this week hailed WTO’s intellectual property agreement, saying the past two decades show it provides a balanced multilateral foundation for the growth of trade in knowledge-rich products and services.
Today, the World Health Organization gave a press briefing to update journalists on what to expect in the near future on Ebola treatments and vaccines.
Local production of medicines in developing countries is key to advancing universal health coverage, but other factors need to be considered, such as the involvement of all stakeholders and policy coherence in governments, according to speakers attending the World Investment Forum this week. Several speakers called for a paradigm shift in global health.
The Universities Allied for Essential Medicines (UAEM) organised a panel at the World Trade Organization Public Forum this week on new approaches in university management of intellectual property. The panel gathered a diverse panel of experts giving their take on possible solutions to less innovation and higher prices of drugs, and the role of publicly-funded research.
Health Action International Europe, and Oxfam today issued a briefing paper entitled, “Trading Away Access to Medicines: How the European trade agenda continues to undermine access to medicines.” The paper argues that new concerns such as the ebola virus and the threat of unchecked antimicrobial resistance show the need for a new model for financing pharmaceutical research and development.
The World Health Organization has published an analysis of the patent situation for new hepatitis treatments, and a call for possible pharmaceutical products for prequalification.
A side event to this week’s World Intellectual Property Organization annual General Assembly highlighted the work of the Geneva-based Medicines Patent Pool in fighting HIV/AIDS, and discussed whether it makes sense for the patent pool model to be extended to other diseases.
Gilead on 15 September struck voluntary licence deals with seven India-based generic manufacturers to expand access to its hepatitis C innovative drugs in developing countries. With a limited territory covered, this, yet deserving, pact raises doubts about the coherence of Indian counterparts at a time when there are no relevant patents in India, several pre-grant oppositions have been filed and unrestrained competition by compulsory licences could have been pursued, writes Daniele Dionisio.
What is a mandatory licence? Mandatory licenses are a legal remedy within the intellectual property flexibilities provided by the World Trade Organization allowing a government to grant permission to third parties to produce a patented product or use a patented process without the consent of the patentee, in order to address a priority status for the country.
The world and the global health community have been taken by surprise by the worst outbreak of Ebola so far. The World Health Organization today (5 September) said a vaccine could be available in November 2014 if proven safe. So far, according to the WHO, intellectual property issues have not acted as a barrier to accessing potential treatments and vaccines, and the focus for now is on emergency measures to find health solutions.